Incyte Corporation

710 articles about Incyte Corporation

• Incyte Corporation’s JAK Inhibitor Demonstrates Rapid and Marked Clinical Improvement in Rheumatoid Arthritis Patients

  10/27/2008

• Incyte Corporation to Report Third Quarter 2008 Financial Results and Provide Update on Drug Discovery & Development Programs on November 6

  10/23/2008

• Incyte Corporation to Host Webcast and Conference Call on October 26, 10:30 p.m. Eastern Time / 7:30 p.m. Pacific Time

  10/23/2008

• Incyte Corporation To Present At JMP Securities Third Annual Healthcare Focus Conference

  10/1/2008

• Incyte Corporation Appoints Chief Commercial Officer

  9/19/2008

• Incyte Corporation's Topical JAK Inhibitor Demonstrates Positive Proof-of-Concept Results in Patients with Mild to Moderate Psoriasis

  9/18/2008

• Incyte Corporation to Present at the UBS Warburg Global Life Sciences Conference

  9/17/2008

• Incyte Corporation Announces Closing of Public Offering of Common Stock

  8/7/2008

• Incyte Corporation Announces Pricing of Public Offering of 10,500,000 Shares of Common Stock

  8/1/2008

• Incyte Corporation Reports Progress in Multiple Clinical Programs; Announces Second Quarter Financial Results

  7/30/2008

• Incyte Corporation Announces Proposed Public Offering of 9,000,000 Shares of Common Stock

  7/30/2008

• Incyte Corporation to Report Second Quarter 2008 Financial Results and Provide Update on Drug Discovery & Development Programs on July 31

  7/23/2008

• Incyte Corporation's JAK Inhibitor Demonstrates Marked Clinical Benefits in Phase IIa Rheumatoid Arthritis Study

  6/12/2008

• Incyte Corporation to Host EULAR Webcast and Conference Call on June 12

  6/12/2008

• Incyte Corporation's Selective Oral Inhibitor of 11beta-HSD1 Demonstrates Improvements in Insulin Sensitivity and Lowers Cholesterol Levels in Type 2 Diabetics

  6/10/2008

• Incyte Corporation to Present at Upcoming Investor Conferences

  6/4/2008

• Incyte Corporation Shares Fall As Some Analysts Say Bone Marrow Drug Treats Symptoms, Not Disease Itself

  6/4/2008

• Incyte Corporation's Novel JAK Inhibitor Demonstrates Rapid Clinical Benefits in Ongoing Phase I/II Myelofibrosis Study

  6/2/2008

• Incyte Corporation Reports First Quarter Financial Results and Positive Clinical Progress in Multiple Programs

  4/30/2008

• Incyte Corporation to Report First Quarter 2008 Financial Results and Provide Update on Drug Discovery & Development Programs on April 30

  4/17/2008